312 related articles for article (PubMed ID: 24497570)
1. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.
Zadra G; Photopoulos C; Tyekucheva S; Heidari P; Weng QP; Fedele G; Liu H; Scaglia N; Priolo C; Sicinska E; Mahmood U; Signoretti S; Birnberg N; Loda M
EMBO Mol Med; 2014 Apr; 6(4):519-38. PubMed ID: 24497570
[TBL] [Abstract][Full Text] [Related]
2. AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy.
Schiewer MJ; Knudsen KE
EMBO Mol Med; 2014 Apr; 6(4):439-41. PubMed ID: 24562461
[TBL] [Abstract][Full Text] [Related]
3. CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis.
Penfold L; Woods A; Muckett P; Nikitin AY; Kent TR; Zhang S; Graham R; Pollard A; Carling D
Cancer Res; 2018 Dec; 78(24):6747-6761. PubMed ID: 30242113
[TBL] [Abstract][Full Text] [Related]
4. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
O'Brien AJ; Villani LA; Broadfield LA; Houde VP; Galic S; Blandino G; Kemp BE; Tsakiridis T; Muti P; Steinberg GR
Biochem J; 2015 Jul; 469(2):177-87. PubMed ID: 25940306
[TBL] [Abstract][Full Text] [Related]
5. The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.
Akhtar N; Syed DN; Khan MI; Adhami VM; Mirza B; Mukhtar H
Oncotarget; 2016 Jan; 7(4):3819-31. PubMed ID: 26683363
[TBL] [Abstract][Full Text] [Related]
6. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
Guo D; Hildebrandt IJ; Prins RM; Soto H; Mazzotta MM; Dang J; Czernin J; Shyy JY; Watson AD; Phelps M; Radu CG; Cloughesy TF; Mischel PS
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12932-7. PubMed ID: 19625624
[TBL] [Abstract][Full Text] [Related]
7. Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662.
Ducommun S; Ford RJ; Bultot L; Deak M; Bertrand L; Kemp BE; Steinberg GR; Sakamoto K
Am J Physiol Endocrinol Metab; 2014 Mar; 306(6):E688-96. PubMed ID: 24425763
[TBL] [Abstract][Full Text] [Related]
8. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
9. Salicylate enhances the response of prostate cancer to radiotherapy.
Broadfield LA; Marcinko K; Tsakiridis E; Zacharidis PG; Villani L; Lally JSV; Menjolian G; Maharaj D; Mathurin T; Smoke M; Farrell T; Muti P; Steinberg GR; Tsakiridis T
Prostate; 2019 Apr; 79(5):489-497. PubMed ID: 30609074
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
11. Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells.
Lin VC; Tsai YC; Lin JN; Fan LL; Pan MH; Ho CT; Wu JY; Way TD
J Agric Food Chem; 2012 Jun; 60(25):6399-407. PubMed ID: 22670709
[TBL] [Abstract][Full Text] [Related]
12. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.
Zadra G; Priolo C; Patnaik A; Loda M
Clin Cancer Res; 2010 Jul; 16(13):3322-8. PubMed ID: 20423984
[TBL] [Abstract][Full Text] [Related]
13. Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1/FASN-driven metabolism and AR.
Hsieh PF; Jiang WP; Basavaraj P; Huang SY; Ruangsai P; Wu JB; Huang GJ; Huang WC
Phytomedicine; 2021 Dec; 93():153806. PubMed ID: 34740154
[TBL] [Abstract][Full Text] [Related]
14. Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo.
Chen D; Banerjee S; Cui QC; Kong D; Sarkar FH; Dou QP
PLoS One; 2012; 7(10):e47186. PubMed ID: 23056607
[TBL] [Abstract][Full Text] [Related]
15. AMPK activation protects against prostate cancer by inducing a catabolic cellular state.
Penfold L; Woods A; Pollard AE; Arizanova J; Pascual-Navarro E; Muckett PJ; Dore MH; Montoya A; Whilding C; Fets L; Mokochinski J; Constantin TA; Varela-Carver A; Leach DA; Bevan CL; Nikitin AY; Hall Z; Carling D
Cell Rep; 2023 Apr; 42(4):112396. PubMed ID: 37061917
[TBL] [Abstract][Full Text] [Related]
16. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.
Tennakoon JB; Shi Y; Han JJ; Tsouko E; White MA; Burns AR; Zhang A; Xia X; Ilkayeva OR; Xin L; Ittmann MM; Rick FG; Schally AV; Frigo DE
Oncogene; 2014 Nov; 33(45):5251-61. PubMed ID: 24186207
[TBL] [Abstract][Full Text] [Related]
17. The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.
Shen M; Zhang Z; Ratnam M; Dou QP
J Cell Physiol; 2014 Jun; 229(6):688-95. PubMed ID: 24129850
[TBL] [Abstract][Full Text] [Related]
18. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
19.
Huang SY; Huang GJ; Wu HC; Kao MC; Huang WC
Molecules; 2018 Oct; 23(10):. PubMed ID: 30301150
[TBL] [Abstract][Full Text] [Related]
20. A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.
Khan AS; Frigo DE
Nat Rev Urol; 2017 Mar; 14(3):164-180. PubMed ID: 28169991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
